These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32255703)

  • 21. Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development.
    Zaratin P; Comi G; Coetzee T; Ramsey K; Smith K; Thompson A; Panzara M
    Trends Pharmacol Sci; 2016 Oct; 37(10):808-810. PubMed ID: 27554755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Competition: Unlikely partnerships.
    Savage N
    Nature; 2016 May; 533(7602):S56-8. PubMed ID: 27167391
    [No Abstract]   [Full Text] [Related]  

  • 23. The successes and challenges of open-source biopharmaceutical innovation.
    Allarakhia M
    Expert Opin Drug Discov; 2014 May; 9(5):459-65. PubMed ID: 24702304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Academia-pharma partnerships for novel drug discovery: essential or nice to have?
    Palmer M; Chaguturu R
    Expert Opin Drug Discov; 2017 Jun; 12(6):537-540. PubMed ID: 28394189
    [No Abstract]   [Full Text] [Related]  

  • 25. A renaissance in biomedical innovation: global villages raise effective therapies.
    Collyar D; Chaguturu R
    Future Med Chem; 2015; 7(8):971-4. PubMed ID: 26062394
    [No Abstract]   [Full Text] [Related]  

  • 26. What is the most important approach in current drug discovery: doing the right things or doing things right?
    Elebring T; Gill A; Plowright AT
    Drug Discov Today; 2012 Nov; 17(21-22):1166-9. PubMed ID: 22569181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring open innovation with a patient focus in drug discovery: an evolving paradigm of patient engagement.
    Allarakhia M
    Expert Opin Drug Discov; 2015 Jun; 10(6):571-8. PubMed ID: 25872566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Innovating openly: researchers and patients turn to crowdsourcing to collaborate on clinical trials, drug discovery, and more.
    Morton CC
    IEEE Pulse; 2014; 5(1):63-7. PubMed ID: 25296376
    [No Abstract]   [Full Text] [Related]  

  • 29. Alternative business models for drug discovery.
    Bunin BA; Ekins S
    Drug Discov Today; 2011 Aug; 16(15-16):643-5. PubMed ID: 21745585
    [No Abstract]   [Full Text] [Related]  

  • 30. Models for open innovation in the pharmaceutical industry.
    Schuhmacher A; Germann PG; Trill H; Gassmann O
    Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Organizing for innovation: towards successful translational research.
    West W; Nightingale P
    Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level.
    Kamel N; Compton C; Middelveld R; Higenbottam T; Dahlén SE
    Eur Respir J; 2008 May; 31(5):924-6. PubMed ID: 18448501
    [No Abstract]   [Full Text] [Related]  

  • 33. Brazil: An emerging partner in drug R&D.
    Rodrigues DG
    IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrative knowledge management to enhance pharmaceutical R&D.
    Marti-Solano M; Birney E; Bril A; Della Pasqua O; Kitano H; Mons B; Xenarios I; Sanz F
    Nat Rev Drug Discov; 2014 Apr; 13(4):239-40. PubMed ID: 24687050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug discovery chemistry: a primer for the non-specialist.
    Jordan AM; Roughley SD
    Drug Discov Today; 2009 Aug; 14(15-16):731-44. PubMed ID: 19416759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [From drug cost to drug price: steps and decisional processes].
    Bruyninckx M; Nourissier C
    Presse Med; 2012 May; 41 Suppl 1():S40-3. PubMed ID: 22487715
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Open partnering of integrated drug discovery: continuing evolution of the pharmaceutical model.
    Hutchins S; Torphy T; Muller C
    Drug Discov Today; 2011 Apr; 16(7-8):281-3. PubMed ID: 21335101
    [No Abstract]   [Full Text] [Related]  

  • 39. Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.
    Laverty H; Gunn M; Goldman M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):545-8. PubMed ID: 23136843
    [No Abstract]   [Full Text] [Related]  

  • 40. Mergers and innovation in the pharmaceutical industry.
    Comanor WS; Scherer FM
    J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.